Loading stock data…
GERN
$1.12-0.01 (-0.88%)
After Hours$1.13+0.01 (+0.89%)· Last close Jun 9
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Geron Corporation in the Healthcare sector is trading at $1.12 with a market capitalization of $802M. Wall Street consensus targets $3.40 (5 analysts), implying a +203.6% move over the next 12 months. The stock is currently near its 52-week low of $1.04, remaining 20.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +203.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.12
Potential Downside
0%
Whystock Fair Value$1.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$801.90M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.97%
Volume
Today's trading volume
13.53M
Recent News
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN)
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy?
Geron Corporation (NASDAQ:GERN) is one of the 10 Best US Stocks Under $5 to Buy. On May 7, Wedbush reiterated its Outperform rating on Geron Corporation (NASDAQ:GERN) with a price target of $5 on the stock. This update comes after the company reported results for the first quarter of 2026 and recent business developments. During […]
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance
Geron (GERN) has put its first quarter 2026 results front and center for investors, highlighting higher RYTELO revenue, a smaller net loss and reaffirmed full year guidance as the core of the latest update. See our latest analysis for Geron. Despite the Q1 beat and reaffirmed guidance, Geron’s recent share price performance has been weak, with a 30 day share price return of 16.1% and a 7 day share price return of 5.2%. The 1 year total shareholder return of 15.9% contrasts with a 3 year total...
Geron Corporation (NASDAQ:GERN) Just Reported And Analysts Have Been Lifting Their Price Targets
Geron Corporation ( NASDAQ:GERN ) just released its latest quarterly results and things are looking bullish. Revenues...